Key result
Tanshinone IIA increases superoxide dismutase, reduces malondialdehyde, and limits infarct area in rat ischemia-reperfusion models.
Why the study?
Tanshinone IIA has been extensively studied in animal models for controlling myocardial ischemia–reperfusion injury, but a comprehensive evaluation of its therapeutic effects in rat models was needed.
Does tanshinone IIA improve superoxide dismutase and malondialdehyde levels in rat models with myocardial ischemia-reperfusion injury?
Meta-Analysis (n=15)
Does tanshinone IIA improve superoxide dismutase and malondialdehyde levels in rat models with myocardial ischemia-reperfusion injury?
Tanshinone IIA demonstrates a myocardial protective effect by ameliorating oxidative stress and reducing infarct size in rat models of ischemia-reperfusion injury.
Supports preclinical cardioprotection in ischemia-reperfusion models; leaves open translation to human trials.
Background: Bunge. Recently, tanshinone IIA has been studied extensively in animal models for controlling MIRI. Therefore, we conducted a meta-analysis on the application of tanshinone IIA in rat models with MIRI to evaluate the therapeutic effects of tanshinone IIA. Methods: A comprehensive search was conducted across PubMed, Web of Science, Embase, the Cochrane Library, the China National Knowledge Infrastructure database, the Wanfang database, and the Chinese Scientific Journal Database to gather studies on tanshinone IIA intervention in rat models with MIRI.We employed SYRCLE's risk of bias tool to assess study quality. The primary outcome indicators were superoxide dismutase (SOD) and malondialdehyde (MDA). Myocardial infarction area was a secondary outcome indicator. This study was registered at PROSPERO (registration number CRD 42022344447). Results: According to the inclusion and exclusion criteria, 15 eligible studies were selected from 295 initially identified studies. In rat models with MIRI, tanshinone IIA significantly increased SOD levels while reducing MDA levels and myocardial infarction area. Moreover, the duration of myocardial ischemia influenced the effectiveness of tanshinone IIA. However, additional high-quality research studies are needed to establish the efficacy and definitive guidelines for the use of tanshinone IIA. Animal studies demonstrated that tanshinone IIA exerted a significant therapeutic effect when the ischemia duration was less than 40 minutes. Tanshinone IIA was found to be more effective when administered via intravenous, intraperitoneal, and intragastric routes at doses above 5 mg/kg. Additionally, treatment with tanshinone IIA at all stages-prior to myocardial ischemia, after ischemia but before reperfusion, prior to ischemia and after reperfusion, and after reperfusion-showed satisfactory results. Conclusions: Tanshinone IIA enhanced SOD activity and reduced MDA levels, thereby ameliorating oxidative stress damage during MIRI. Additionally, it reduced the myocardial infarction area, indicating its effectiveness in mitigating MIRI-induced damage in rats and demonstrating a myocardial protective effect. These findings contribute valuable insights for developing MIRI treatment strategies.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2024) conducted a meta-analysis in Myocardial ischemia-reperfusion injury (n=15). Tanshinone IIA was evaluated on Superoxide dismutase (SOD) and malondialdehyde (MDA). Tanshinone IIA significantly increased superoxide dismutase levels and reduced malondialdehyde levels and myocardial infarction area in rat models with myocardial ischemia-reperfusion injury.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: